Impact of sheath diameter of different sheath types on vascular complications and mortality in transfemoral TAVI approaches using the Proglide closure device
Evaluation of the impact of the sheath diameter on vascular complications and mortality in transfemoral aortic valve implantation. Between 2012 and 2014, 183 patients underwent the procedure using a sheath diameter of 18-24 F. This collective was divided into two groups: group 1, with a sheath diame...
Saved in:
Published in | PloS one Vol. 12; no. 8; p. e0183658 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
24.08.2017
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
ISSN | 1932-6203 1932-6203 |
DOI | 10.1371/journal.pone.0183658 |
Cover
Summary: | Evaluation of the impact of the sheath diameter on vascular complications and mortality in transfemoral aortic valve implantation.
Between 2012 and 2014, 183 patients underwent the procedure using a sheath diameter of 18-24 F. This collective was divided into two groups: group 1, with a sheath diameter of 18F (G1, n = 94), consisted of patients with 18F Medtronic Sentrant and 18 F Direct Flow sheaths, and group 2 with a sheath diameter of 19-24 F (G2, n = 89) consisted of patients with Edwards expandable e-sheath and Solopath sheaths. Perclose-Proglide® was used as a closure device in all patients.
G1 had significantly more female patients (64.9% vs. 46.1% in G2, p = 0.01) and the average BMI was lower (26 ± 4.5% vs. 27.4 ± 4.7%, p = 0.03). There was no significant difference in the incidence of major and minor vascular complications (G1: 12.8% vs. G2: 12.4%, p = 0.9). 30-day mortality was similar in both groups (G1: 6.4 ± 2.5% [95% CI: 0.88-0.98], G2: 3.7 ± 1.9% [95% CI: 0.92-0.99]. The Kaplan Meier analysis of survival revealed no significant differences either.
The difference in sheath diameter had no effect on either incidence or severity of vascular complications. There was no impact on mortality either. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: Zisis Dimitriadis, Marcus Wiemer, Cornelia Piper, Thomas Bitter, Marios Vlachojannis, Dieter Horstkotte, Lothar Faber declare that they have no conflict of interest. Smita Scholtz and Werner Scholtz have received honoraria for lectures from Medtronic and Direct Flow Medical and for proctor activities from Direct Flow Medical. Jochen Börgermann has received horonaria for lectures from Edwards, Maquet, Medtronic and Symetis and for proctor activities from Medtronic Stephan Ensminger is proctor and consultant for Edwards Lifesciences™, proctor and member of the SAB of JenaValve™, received speaker honoraria from Edwards Lifesciences™ and Symetis™, received travel compensation from Edwards Lifesciences™, JenaValve™ and Symetis™. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0183658 |